DK3274366T3 - Kimær antigenreceptor - Google Patents

Kimær antigenreceptor Download PDF

Info

Publication number: DK3274366T3
Authority: DK; Denmark
Prior art keywords: antigen receptor; chemical antigen; chemical; receptor; antigen
Prior art date: 2015-03-23

Application number

DK16712424.7T

Other languages

English (en)

Inventor

Martin Pulé

Shaun Cordoba

Original Assignee

Ucl Business Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-03-23

Filing date

2016-03-22

Publication date

2020-02-10

2016-03-22 Application filed by Ucl Business Ltd filed Critical Ucl Business Ltd

2020-02-10 Application granted granted Critical

2020-02-10 Publication of DK3274366T3 publication Critical patent/DK3274366T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4244—Enzymes
- A61K40/4251—Kinases, e.g. Raf or Src
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/23—On/off switch
- A61K2239/24—Dimerizable CARs; CARs with adapter
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Medicinal Chemistry (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
Hematology (AREA)
Pharmacology & Pharmacy (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

DK16712424.7T 2015-03-23 2016-03-22 Kimær antigenreceptor DK3274366T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB1504840.8A GB201504840D0 (en)	2015-03-23	2015-03-23	Chimeric antigen receptor
PCT/GB2016/050795 WO2016151315A1 (en)	2015-03-23	2016-03-22	Chimeric antigen receptor

Publications (1)

Publication Number	Publication Date
DK3274366T3 true DK3274366T3 (da)	2020-02-10

Family

ID=53052211

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK16712424.7T DK3274366T3 (da)	2015-03-23	2016-03-22	Kimær antigenreceptor

Country Status (21)

Country	Link
US (1)	US11058722B2 (da)
EP (1)	EP3274366B8 (da)
JP (3)	JP6675417B2 (da)
KR (1)	KR102174280B1 (da)
CN (1)	CN107406518B (da)
AU (1)	AU2016238583B2 (da)
BR (1)	BR112017018252A2 (da)
CA (1)	CA2978852C (da)
CL (1)	CL2017002413A1 (da)
DK (1)	DK3274366T3 (da)
ES (1)	ES2773527T3 (da)
GB (1)	GB201504840D0 (da)
HU (1)	HUE047929T2 (da)
IL (1)	IL254254B (da)
MX (1)	MX371384B (da)
PL (1)	PL3274366T3 (da)
PT (1)	PT3274366T (da)
RU (1)	RU2752880C2 (da)
SG (1)	SG11201706940QA (da)
WO (1)	WO2016151315A1 (da)
ZA (1)	ZA201705682B (da)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2014117121A1 (en)	2013-01-28	2014-07-31	St. Jude Children's Research Hospital, Inc.	A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
US11385233B2 (en)	2015-03-05	2022-07-12	Autolus Limited	Methods of depleting malignant T-cells
US11885806B2 (en)	2014-03-05	2024-01-30	Autolus Limited	Method for depleting malignant T-cells
GB201403972D0 (en)	2014-03-06	2014-04-23	Ucl Business Plc	Chimeric antigen receptor
GB201405845D0 (en)	2014-04-01	2014-05-14	Ucl Business Plc	Signalling system
KR102211120B1 (ko)	2014-05-15	2021-02-03	내셔널 유니버시티 오브 싱가포르	변형된 천연 살해 세포 및 그의 용도
GB201415347D0 (en)	2014-08-29	2014-10-15	Ucl Business Plc	Signalling system
GB201501936D0 (en) *	2015-02-05	2015-03-25	Ucl Business Plc	Signalling system
BR112017024757A2 (pt)	2015-05-18	2018-11-13	TCR2 Therapeutics Inc.	composições e métodos para reprogramação de tcr utilizando proteínas de fusão
EP3443001B1 (en)	2016-04-11	2025-04-30	Obsidian Therapeutics, Inc.	REGULATED BIOCIRCUIT SYSTEMS
GB201610512D0 (en)	2016-06-16	2016-08-03	Autolus Ltd	Chimeric antigen receptor
WO2018026953A1 (en)	2016-08-02	2018-02-08	TCR2 Therapeutics Inc.	Compositions and methods for tcr reprogramming using fusion proteins
MX2019003899A (es)	2016-10-07	2019-08-14	Tcr2 Therapeutics Inc	Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion.
AU2017363311A1 (en)	2016-11-22	2019-06-13	TCR2 Therapeutics Inc.	Compositions and methods for TCR reprogramming using fusion proteins
IL269553B2 (en)	2017-03-27	2025-10-01	Nat Univ Singapore	Truncated NKG2D chimeric receptors and their uses in immunotherapy with natural killer cells
WO2018182511A1 (en)	2017-03-27	2018-10-04	National University Of Singapore	Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
EP3601573A4 (en) *	2017-03-29	2020-12-23	Sunnybrook Research Institute	GENETICALLY MODIFIED T-LYMPHOCYTES MODULATING MOLECULES AND ASSOCIATED PROCEDURES FOR USE
BR112019023608A2 (pt)	2017-05-12	2020-05-26	Crispr Therapeutics Ag	Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
US11166985B2 (en)	2017-05-12	2021-11-09	Crispr Therapeutics Ag	Materials and methods for engineering cells and uses thereof in immuno-oncology
US20210130775A1 (en) *	2017-08-02	2021-05-06	Autolus Limited	Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed
EP3704150A1 (en) *	2017-11-01	2020-09-09	F. Hoffmann-La Roche AG	The compbody - a multivalent target binder
GB201801831D0 (en) *	2018-02-05	2018-03-21	Autolus Ltd	Chimeric receptor
CN111801348A (zh)	2018-02-09	2020-10-20	新加坡国立大学	活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途
SG11202008976YA (en)	2018-04-02	2020-10-29	Nat Univ Singapore	Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
EP3790629A1 (en)	2018-05-11	2021-03-17	CRISPR Therapeutics AG	Methods and compositions for treating cancer
AU2019269118B2 (en)	2018-05-15	2025-02-27	Autolus Limited	Chimeric antigen receptor
GB201807870D0 (en)	2018-05-15	2018-06-27	Autolus Ltd	A CD79-specific chimeric antigen receptor
WO2020037178A1 (en) *	2018-08-16	2020-02-20	Memorial Sloan-Kettering Cancer Center	Leucine zipper-based compositions and methods of use
EP3844186A4 (en)	2018-08-29	2022-08-17	National University of Singapore	METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
CN109265550B (zh) *	2018-09-25	2020-09-15	华东师范大学	Bcma抗体、嵌合抗原受体和药物
FI3856775T3 (fi)	2018-09-27	2024-12-04	Autolus Ltd	Kimeerinen antigeenireseptori
JP2022504191A (ja) *	2018-10-05	2022-01-13	ザンクトアンナキンダークレプスフォルシュング	キメラ抗原受容体（ｃａｒ）群
JP2022512594A (ja) *	2018-10-05	2022-02-07	ザンクトアンナキンダークレプスフォルシュング	キメラ抗原受容体（ｃａｒ）の群
GB201817822D0 (en)	2018-10-31	2018-12-19	Autolus Ltd	Binding domain
CA3120563A1 (en)	2018-11-26	2020-06-04	Nkarta, Inc.	Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
KR20210132668A (ko) *	2019-02-21	2021-11-04	아르벨 리미티드	인공 면역감시 키메라 항원 수용체(ai-car) 및 이를 발현하는 세포
WO2020180882A1 (en)	2019-03-05	2020-09-10	Nkarta, Inc.	Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
SG11202109002XA (en)	2019-03-21	2021-09-29	Regeneron Pharma	Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
AU2020267057A1 (en)	2019-04-30	2021-11-18	Crispr Therapeutics Ag	Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19
GB201919017D0 (en)	2019-12-20	2020-02-05	Autolus Ltd	Cell
CN111234033B (zh) *	2020-01-21	2021-05-11	南京北恒生物科技有限公司	多链嵌合抗原受体及其用途
GB202004263D0 (en)	2020-03-24	2020-05-06	Autolus Ltd	Antibody conjugate
GB202005216D0 (en)	2020-04-08	2020-05-20	Autolus Ltd	Cell
GB202006820D0 (en)	2020-05-07	2020-06-24	Autolus Ltd	Cell
GB202017649D0 (en)	2020-11-09	2020-12-23	Autolus Ltd	Polypeptide
CA3172530A1 (en)	2021-02-25	2022-09-01	Spencer PARK	Ror1 targeting chimeric antigen receptor
WO2022204326A1 (en) *	2021-03-24	2022-09-29	The Regents Of The University Of California	Humanized synthetic notch receptors with augmented transactivation domains and uses thereof
GB202115329D0 (en) *	2021-10-25	2021-12-08	Autolus Ltd	Chimeric cytokine receptor
WO2024019961A1 (en) *	2022-07-18	2024-01-25	Cargo Therapeutics, Inc.	Cd2 recruiting chimeric antigen receptors and fusion proteins
US20250242056A1 (en)	2024-01-26	2025-07-31	Regeneron Pharmaceuticals, Inc.	Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
US20250242018A1 (en)	2024-01-26	2025-07-31	Regeneron Pharmaceuticals, Inc.	Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184567A1 (en)	2024-03-01	2025-09-04	Regeneron Pharmaceuticals, Inc.	Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7081443B2 (en)	2002-05-21	2006-07-25	Korea Advanced Institutes Of Science And Technology (Kaist)	Chimeric comp-ang1 molecule
WO2010102518A1 (zh)	2009-03-13	2010-09-16	北京表源生物技术有限公司	一种融合蛋白多聚体
KR101156085B1 (ko) *	2010-01-29	2012-06-20	국립암센터	４－１ｂｂ리간드（４－１ｂｂｌ）오중합체 및 이의 용도
US10745467B2 (en) *	2010-03-26	2020-08-18	The Trustees Of Dartmouth College	VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
WO2013051718A1 (ja) *	2011-10-07	2013-04-11	国立大学法人三重大学	キメラ抗原受容体
EP4541818A3 (en) *	2012-05-25	2025-07-23	Cellectis	Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
ES2714523T3 (es) *	2012-09-04	2019-05-28	Cellectis	Receptor quimérico de antígenos multicatenario y usos del mismo
SI3300745T1 (sl) *	2013-02-15	2020-01-31	The Regents Of The University Of California	Himerni antigenski receptor in postopki njihove uporabe
CN103145849B (zh) *	2013-02-18	2014-06-11	冯振卿	嵌合抗原受体及其用途
AU2014368892B2 (en) *	2013-12-20	2019-06-13	Fred Hutchinson Cancer Center	Tagged chimeric effector molecules and receptors thereof
US20160333108A1 (en)	2014-01-13	2016-11-17	Stephen J. Forman	CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE
GB201415347D0 (en)	2014-08-29	2014-10-15	Ucl Business Plc	Signalling system
GB201610512D0 (en)	2016-06-16	2016-08-03	Autolus Ltd	Chimeric antigen receptor

2015
- 2015-03-23 GB GBGB1504840.8A patent/GB201504840D0/en not_active Ceased
2016
- 2016-03-22 BR BR112017018252-1A patent/BR112017018252A2/pt not_active IP Right Cessation
- 2016-03-22 ES ES16712424T patent/ES2773527T3/es active Active
- 2016-03-22 HU HUE16712424A patent/HUE047929T2/hu unknown
- 2016-03-22 PT PT167124247T patent/PT3274366T/pt unknown
- 2016-03-22 AU AU2016238583A patent/AU2016238583B2/en not_active Ceased
- 2016-03-22 KR KR1020177030391A patent/KR102174280B1/ko active Active
- 2016-03-22 CN CN201680017370.3A patent/CN107406518B/zh not_active Expired - Fee Related
- 2016-03-22 EP EP16712424.7A patent/EP3274366B8/en active Active
- 2016-03-22 PL PL16712424T patent/PL3274366T3/pl unknown
- 2016-03-22 DK DK16712424.7T patent/DK3274366T3/da active
- 2016-03-22 RU RU2017132978A patent/RU2752880C2/ru active
- 2016-03-22 SG SG11201706940QA patent/SG11201706940QA/en unknown
- 2016-03-22 CA CA2978852A patent/CA2978852C/en active Active
- 2016-03-22 JP JP2017549766A patent/JP6675417B2/ja not_active Expired - Fee Related
- 2016-03-22 US US15/560,558 patent/US11058722B2/en active Active
- 2016-03-22 MX MX2017010552A patent/MX371384B/es active IP Right Grant
- 2016-03-22 WO PCT/GB2016/050795 patent/WO2016151315A1/en not_active Ceased
2017
- 2017-08-21 ZA ZA2017/05682A patent/ZA201705682B/en unknown
- 2017-08-31 IL IL254254A patent/IL254254B/en active IP Right Grant
- 2017-09-25 CL CL2017002413A patent/CL2017002413A1/es unknown
2020
- 2020-01-09 JP JP2020001971A patent/JP2020048588A/ja not_active Withdrawn
2022
- 2022-12-16 JP JP2022201192A patent/JP2023021396A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
JP2020048588A (ja)	2020-04-02
CA2978852A1 (en)	2016-09-29
JP2018510639A (ja)	2018-04-19
ZA201705682B (en)	2018-12-19
EP3274366B8 (en)	2020-02-12
ES2773527T3 (es)	2020-07-13
JP2023021396A (ja)	2023-02-10
RU2752880C2 (ru)	2021-08-11
BR112017018252A2 (pt)	2018-04-10
CA2978852C (en)	2021-10-19
AU2016238583A1 (en)	2017-09-28
EP3274366B1 (en)	2019-12-11
MX2017010552A (es)	2018-03-14
KR102174280B1 (ko)	2020-11-04
RU2017132978A (ru)	2019-04-08
SG11201706940QA (en)	2017-09-28
PL3274366T3 (pl)	2020-06-15
WO2016151315A1 (en)	2016-09-29
CL2017002413A1 (es)	2018-03-16
US20180050065A1 (en)	2018-02-22
JP6675417B2 (ja)	2020-04-01
CN107406518A (zh)	2017-11-28
RU2017132978A3 (da)	2019-06-24
US11058722B2 (en)	2021-07-13
KR20180009738A (ko)	2018-01-29
NZ735267A (en)	2021-04-30
IL254254B (en)	2021-04-29
EP3274366A1 (en)	2018-01-31
IL254254A0 (en)	2017-10-31
AU2016238583B2 (en)	2020-08-13
HUE047929T2 (hu)	2020-05-28
GB201504840D0 (en)	2015-05-06
CN107406518B (zh)	2022-02-01
PT3274366T (pt)	2020-01-30
MX371384B (es)	2020-01-28

Publication	Publication Date	Title
DK3194434T3 (da)	2019-08-26	Kimære antigenreceptorer
PL3274366T3 (pl)	2020-06-15	Chimeryczny receptor antygenowy
DK3230321T3 (da)	2019-10-28	Kimære bcma-antigenreceptorer
EP3538557A4 (en)	2020-11-18	ANTI-CD47 ANTIBODY
IL251963A0 (en)	2017-06-29	Anti-pd-1 antibodies
DK3126390T3 (da)	2020-01-20	Cd33-specifikke kimære antigenreceptorer til cancerimmunterapi
DK3344654T3 (da)	2021-01-18	Anti-lag-3-antistoffer
IL258502A (en)	2018-05-31	Chimeric antigen receptors targeted to psca
EP3319984C0 (en)	2026-03-11	TAU LINKING ANTIBODIES
DK3283110T3 (da)	2022-05-23	Antistoffer rettet mod interleukin-36-receptor (il-36r)
PL3556777T3 (pl)	2021-07-12	Konstrukty przeciwciał wieloswoistych
DK3350218T3 (da)	2024-04-02	Polyomavirus-neutraliserende antistoffer
PT3101032T (pt)	2019-04-03	Onjugado de anticorpo anti-her2-fármaco
IL256099A (en)	2018-02-28	Antibody
EP3319983C0 (en)	2026-01-28	TAU LINKING ANTIBODIES
HUE060878T2 (hu)	2023-04-28	Anti-transztiretin antitestek
DK3250593T3 (da)	2022-08-22	Anti-transthyretin-antistoffer
IL291164A (en)	2022-05-01	Anti-nme antibody
DK3464336T3 (da)	2022-05-09	Forbindelser
IL257368A (en)	2018-04-30	Antibody
IL268652B (en)	2022-01-01	Chemical composition
DK3484921T3 (da)	2022-02-07	Anti-IL-22R antistoffer
DK3452515T3 (da)	2025-11-17	Her-2-bindende antistoffer
LT3178931T (lt)	2021-04-12	Anti-orai1 antikūnas
EP3160502B1 (en)	2026-05-20	BI-SPECIFIC ANTIBODIES ANTI-IL4-IL13